interview Archives - Page 2 of 13

ESMO China Voice | Professor Bin Shao : Comprehensive Genomic Analysis of Advanced HR+/HER2- Breast Cancer Patients Using Liquid Biopsy

By Mourabit Halima 2024.02.23

HR+/HER2- is the most common subtype of breast cancer, accounting for approximately 65% to 70% of all breast cancer cases. Improving the survival benefits for patients with advanced HR+/HER2- breast cancer has always been a hot topic in this field and a unanimous goal for scholars and experts. Exploring the genomic characteristics of advanced HR+/HER2- breast cancer can enhance our understanding of it, and even identify potential biomarkers that affect its treatment and prognosis. The team led by Professor Li Huiping from the Peking University Cancer Hospital conducted a comprehensive genomic analysis of advanced HR+/HER2- breast cancer patients using liquid biopsy technology. Their research results were included as a poster (abstract number: 496P) at this year's ESMO conference. Oncology Frontier has specially invited Professor Shao Bin to introduce the latest results of this study.

Prof. Jun Ma Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

By Mourabit Halima 2024.02.23

Local time on December 9th, the eagerly awaited 65th American Society of Hematology (ASH) Annual Meeting officially kicked off in San Diego, USA. The Oncology Insight reporting team delved into the forefront, witnessing the impressive presence of "The Voice of China" on the international stage. ASH is one of the largest and most comprehensive international academic conferences in the field of hematology globally, attracting numerous experts and scholars from around the world each year, including a significant representation from China. On the second day of the conference, we had the privilege of interviewing Professor Jun Ma, a leading figure in the field of hematology in China and the Director of the Harbin Institute of Hematology and Oncology. He shared his insights and highlights of this year's conference. Below is Professor Jun Ma's perspective:

ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment

By Lin Zhang 2024.02.23

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening blood disorder. Due to the complexity of complement biology and various pathogenic pathways, there remains a significant unmet clinical need, urgently requiring next-generation drugs with superior efficacy and dosing convenience compared to current therapies. At the recently held 65th American Society of Hematology (ASH) Annual Meeting, Prof. Fengkui Zhang from the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology) and Prof. Bing Han's team from Peking Union Medical College Hospital presented an oral report (Abstract: 572). The study explored the safety and effectiveness of the dual-function C5 antibody/H factor fusion protein KP104 in PNH patients who had not received complement inhibitor treatment. This research brings hope to address this challenging issue and has been selected as a highlight of "ASH 2024." The summarized details are presented below in this issue of "Hematology Insight."

ASH 2023 | West China Team: Exploration of Blinatumomab and Reduced Dosing of Cyclophosphamide before and after Allogeneic Hematopoietic Stem Cell Transplantation

By Mourabit Halima 2024.02.23

The 65th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from December 9 to 12, 2023. ASH Annual Meeting is the largest and most comprehensive international event covering both basic and clinical research in hematlogy. This year, the Hematology Department at West China Hospital, Sichuan University, presented two oral reports, and we delve into these studies:

Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

By Lynn 2024.02.19

Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya's HIV Immunology Translational Research Program, with her current research focus on the immunopathogenic mechanisms of aging in HIV/AIDS patients and their impact on patient health.

Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

By Lynn 2024.02.19

Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring Foundation, member of the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NAID) HIV Vaccine Data and Safety Monitoring Board, and member of various committees including CROI, EACS, and HIV Glasgow.

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

By Lynn 2024.02.19

Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.

ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

By El Bachir MOURABIT 2024.02.18

At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral presentation, using a new intravesical local chemotherapy delivery system. TAR200 is expected to become a treatment method for patients with high-risk non-muscle invasive bladder (HR MIBC) to reduce disease recurrence. In addition, ESMO 2023 also reported TAR201 and EV-302 study. Dr. Andrea Nccchi shared his views on these latest studies in an interview with " Oncology Frontier ".

ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

By Mourabit Halima 2024.02.18

Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled several advancements in prostate cancer research, extending the survival prospects for patients. Although there were some negative results, the research still holds positive significance. "Oncology Frontier" has specially invited Professor Yao Zhu from Fudan University's affiliated Cancer Hospital to provide an in-depth interpretation of these research developments.

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

By Lynn 2024.02.18

Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies.